- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Foundation for Managed Care Pharmacy appoints 4 new trustees
The Board of Trustees of the Foundation for Managed Care Pharmacy (FMCP), the educational and philanthropic arm of the Academy of Managed Care Pharmacy (AMCP), has announced the appointment of 4 new FMCP Trustees.
The Board of Trustees of the Foundation for Managed Care Pharmacy (FMCP), the educational and philanthropic arm of the Academy of Managed Care Pharmacy (AMCP), has announced the appointment of 4 new FMCP Trustees.
They are:
• Suzanne Blackburn, senior vice president, new markets business and product services for Medco Health Solutions;
• Annette Boyer, vice president of business development for CECity.com, Inc.;
• Edwin C. Hedblom, Clinical Research 3M Skin & Wound Care; and
• Peyton Howell, president, consulting services and senior vice president, business development for AmerisourceBergen.
The new Trustees were installed as of July 2011, and will serve a 3-year term.
FMCP is focused on leadership, research and education for managed care pharmacists, according to Norrie Thomas, FMCP's interim executive director.
“The trustees will advise the strategic development of internship programs that examine the role of our profession over the next 5 years with a view toward creating innovation and identifying the best way to foster the development of future leaders,” Thomas told Formulary.
According to Thomas, at the AMCP educational meetings in October, FMCP will present a pre-meeting devoted to research in managed care pharmacy. FMCP will publish a proceedings capturing the presentations and discussions that will guide the research agenda for managed care pharmacy.
“Later this year, in December, the trustees will meet with industry experts as well as academia from across the United States to discuss the changes impacting our profession and will design innovative pilot programs for managed care preceptors and student internship programs,” Thomas said.
The 4 new trustees join President Richard A. Zabinski, PharmD, FAMCP, OptumHealth (A division of UnitedHealth Group); Vice President John Hopkins, BS Pharm, Rocky Mountain Health Plans; Treasurer Robert DeLuca, BS Pharm, Archimedes Pharma US Inc.; and Trustees Ms. Shawn Burke, BS Pharm, FAMCP, RPH, Coventry Health Care; David L. Clark, BS Pharm, MBA, RPH; Perry Cohen, The Pharmacy Group, LLC; William K. Fleming, PharmD, RPh, Humana, Inc.; Kathleen Kaa, PhD, RPh, Genentech, Inc.; Brian Sweet, BS Pharm, MBA, AstraZeneca Pharmaceuticals.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
